Private company

Sio Gene Therapies Inc.

Pharmaceutical preparations company.

Last updated Oct 18, 2026.

Overview

-$71.9MNet income, fiscal 2022²

IndustryPharmaceutical Preparations
Business address1501 Broadway, 12Th Floor, New York, Ny 10036³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-119.1%Return on equity⁴

Financial statements

Operating income⁵⁶⁷⁸⁴-$71.6M in 2022−46% since 2016

Net income⁵⁹⁷⁸⁴²-$71.9M in 2022−46% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Research and development	$76.6M⁵	$134.8M⁵	$141.4M⁶	$87.6M⁷	$47.1M⁸	$24.9M⁴	$53.4M⁴
Operating income	-$133.2M⁵	-$182.0M⁵	-$220.7M⁶	-$128.9M⁷	-$72.2M⁸	-$32.6M⁴	-$71.6M⁴
Interest	$0⁵	$1.1M⁵	$7.5M⁶	$7.5M⁷	$4.4M⁸	$799.0K⁴	$27.0K⁴
Income tax	-$17.0K⁵	-$1.1M⁵	$921.0K⁶	$133.0K⁷	$438.0K⁸	-$212.0K⁴	$259.0K⁴
Net income	-$133.1M⁵	-$181.0M⁵	-$221.6M⁹	-$129.1M⁷	-$72.6M⁸	-$32.4M⁴	-$71.9M²
Earnings per share						-$0.62⁴	-$0.98⁴
Earnings per share (diluted)						-$0.62⁴	-$0.98⁴

Total assets¹¹¹²⁵⁶⁷⁸⁴$75.1M in 2022+6622% since 2015

Total liabilities¹¹¹²⁵⁶⁷⁸⁴$14.7M in 2022+66% since 2015

Shareholders’ equity⁵⁶⁷⁸⁴$60.3M in 2022

Cash⁵⁶⁷⁴$63.7M in 2022

Long-term debt¹²⁵⁶⁷$0 in 2020

Fiscal year	2015	2016	2017	2018	2019	2020	2021	2022
Cash	$0⁵	$276.3M⁵	$212.6M⁵	$154.3M⁶	$107.0M⁷	$80.8M⁴	$119.0M⁴	$63.7M⁴
Current assets	$1.1M¹¹	$282.1M¹²	$219.7M⁵	$158.3M⁶	$114.6M⁷	$85.4M⁸	$132.3M⁴	$71.7M⁴
Total assets	$1.1M¹¹	$282.5M¹²	$222.5M⁵	$160.8M⁶	$122.7M⁷	$93.7M⁸	$135.1M⁴	$75.1M⁴
Current liabilities	$3.9M¹¹	$15.8M¹²	$46.3M⁵	$46.6M⁶	$43.5M⁷	$32.0M⁸	$10.8M⁴	$13.0M⁴
Long-term debt		$0¹²	$51.4M⁵	$42.9M⁶	$23.0M⁷	$0⁷
Total liabilities	$8.9M¹¹	$15.8M¹²	$97.7M⁵	$89.5M⁶	$66.5M⁷	$32.1M⁸	$11.8M⁴	$14.7M⁴
Shareholders’ equity	-$7.8M⁵	$266.7M⁵	$124.8M⁶	$71.3M⁷	$56.2M⁸	$61.6M⁴	$123.4M⁴	$60.3M⁴
Shares outstanding	75.0M shares¹²	99.2M shares¹¹	107.4M shares¹²	107.8M shares⁵	22.8M shares⁶	40.3M shares⁷	69.6M shares⁸	73.7M shares⁴

Cash from operations⁷⁸⁴-$60.3M in 2022−55% since 2019

Fiscal year	2015	2016	2017	2018	2019	2020	2021	2022
Cash from operations					-$134.2M⁷	-$67.5M⁸	-$46.6M⁴	-$60.3M⁴

Compare Sio Gene Therapies Inc. with another company

Leadership

Who has led Sio Gene Therapies Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

David W. Nassif2021–2022

20202025

Chief executive officerDavid W. Nassif Feb 10, 2022 to Feb 10, 2022¹³
Chief executive officerPavan Cheruvu Feb 15, 2018 to Dec 9, 2021¹⁴
Chief financial officerDavid W. Nassif Mar 22, 2021 to Feb 10, 2022¹⁵

Board members and other officers (36)

Chief Commercial OfficerParag Meswani V. Feb 7, 2022 to Feb 10, 2022¹⁶
Principal Financial OfficerDavid W. Nassif Jul 2, 2019 to Jun 15, 2020¹⁷
Principal Executive OfficerPavan Cheruvu Sep 24, 2019 to Jul 10, 2020¹⁸
EVP of R&DGavin Corcoran Jul 10, 2018 to Apr 19, 2021¹⁹
Chief Medical OfficerIlise Lombardo Aug 17, 2018 to Aug 17, 2018²⁰
Principal Executive OfficerDavid Hung Apr 11, 2017 to Jan 3, 2018²¹
Principal Operating OfficerMarion McCourt Apr 11, 2017 to Apr 11, 2017²²
Principal Fin & Acct OfficerAlan S. Roemer Jun 10, 2015 to Jun 10, 2015²³
Chief Admin Officer and GCChristine Mikail Cvijic Jun 10, 2015 to May 3, 2016²⁴
Chief Development OfficerLawrence Friedhoff Md. Phd. Jun 10, 2015 to May 2, 2017²⁵
Head,Global Trans & Risk MgmtMarianne L. Romeo Jun 10, 2015 to May 3, 2016²⁶
Pres&Chief Commercial OfficerMark Altmeyer Jun 10, 2015 to Mar 16, 2018²⁷
Principal Executive OfficerVivek Ramaswamy Jun 10, 2015 to May 3, 2016²⁸
Principal Financial OfficerGregory M. Weinhoff Aug 18, 2015 to Mar 16, 2018²⁹
Principal Accounting OfficerMichael Adasczik Aug 18, 2015 to May 2, 2017³⁰
Board memberDavid W. Nassif Feb 10, 2022 to Feb 10, 2022¹³
Board memberEric Venker Feb 19, 2020 to Feb 19, 2020³¹
Board memberKristiina Vuori Md. Oct 7, 2020 to Apr 19, 2021³²
Board memberPavan Cheruvu Apr 17, 2019 to Dec 9, 2021³³
Board memberSenthil Vel Sundaram Jul 1, 2019 to Apr 19, 2021³⁴
Board memberGeorge Bickerstaff Feb 15, 2018 to Apr 17, 2019³⁵
Board memberRoger Jeffs Feb 15, 2018 to Apr 17, 2019³⁶
Board memberFrank Torti Oct 5, 2018 to Apr 19, 2021³⁷
Board memberDavid Hung Apr 11, 2017 to Jan 3, 2018²¹
Board memberKathryn E. Falberg Apr 11, 2017 to May 16, 2017³⁸
Board memberW. Anthony Vernon Apr 11, 2017 to May 16, 2017³⁹
Board memberClarence Patrick Machado Jul 19, 2017 to Jul 19, 2017⁴⁰
Board memberGary P. Pisano May 20, 2016 to May 2, 2017⁴¹
Board memberAtul Pande Jun 10, 2015 to Apr 19, 2021⁴²
Board memberBerndt Modig Jun 10, 2015 to Apr 19, 2021⁴³
Board memberIlan Oren Jun 10, 2015 to Jun 14, 2018⁴⁴
Board memberLawrence S. Olanoff Jun 10, 2015 to May 2, 2017⁴⁵
Board memberMarianne L. Romeo Jun 10, 2015 to May 3, 2016²⁶
Board memberVivek Ramaswamy Jun 10, 2015 to May 3, 2016²⁸
General counselMathew C. Bazley Oct 3, 2018 to Apr 17, 2019⁴⁶
General counselStephen Frederick Mohr Jun 6, 2017 to Mar 16, 2018⁴⁷

Former names

Axovant Gene Therapies Ltd.Jun 6, 2019 to Nov 13, 2020³
Roivant Neurosciences Ltd.Mar 24, 2015 to Mar 24, 2015³
Axovant Sciences Ltd.Jan 8, 2015 to Apr 18, 2019³

Timeline

Feb 10, 2022New chief executive David W. Nassif becomes CEO¹³
Feb 15, 2018New chief executive Pavan Cheruvu becomes CEO¹⁴

Filings

46 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 20 major events, 5 insider forms, 4 large holders, 11 other. The latest 20:

Apr 25, 202315-12G EDGAR
Apr 24, 2023EFFECT EDGAR
Apr 17, 2023POS AM EDGAR
Apr 17, 2023S-8 POS EDGAR
Apr 6, 202325 EDGAR
Apr 6, 20238-K EDGAR
Mar 17, 2023DEFA14A EDGAR
Mar 15, 20238-K EDGAR
Feb 21, 2023DEFM14A EDGAR
Feb 14, 2023DEFA14A EDGAR
Feb 14, 20238-K EDGAR
Feb 14, 202310-Q EDGAR
Feb 13, 2023SC 13G/A EDGAR
Feb 10, 2023SC 13G EDGAR
Feb 9, 2023PREM14A EDGAR
Dec 14, 2022DEFA14A EDGAR
Dec 14, 20228-K EDGAR
Nov 10, 20228-K EDGAR
Nov 10, 202210-Q EDGAR
Sep 14, 20228-K EDGAR

The 46 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 4 such filings since October 2021:

Feb 13, 2023SC 13G/A
Feb 10, 2023SC 13G
Feb 14, 2022SC 13G/A
Feb 11, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSio Gene Therapies Inc. filings on SEC EDGAR
2
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2022
3
SEC EDGARSio Gene Therapies Inc. filings on SEC EDGAR
4
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2022
5
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2016
6
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2018
7
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2019
8
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2020
9
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2018
10
SEC EDGARSio Gene Therapies Inc. 10-Q for fiscal 2022
11
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2015
12
SEC EDGARSio Gene Therapies Inc. 10-K for fiscal 2016
13
SEC EDGARDavid W. Nassif, Chief executive officer
14
SEC EDGARPavan Cheruvu, Chief executive officer
15
SEC EDGARDavid W. Nassif, Chief financial officer
16
SEC EDGARParag Meswani V., Chief Commercial Officer
17
SEC EDGARDavid W. Nassif, Principal Financial Officer
18
SEC EDGARPavan Cheruvu, Principal Executive Officer
19
SEC EDGARGavin Corcoran, EVP of R&D
20
SEC EDGARIlise Lombardo, Chief Medical Officer
21
SEC EDGARDavid Hung, Principal Executive Officer
22
SEC EDGARMarion McCourt, Principal Operating Officer
23
SEC EDGARAlan S. Roemer, Principal Fin & Acct Officer
24
SEC EDGARChristine Mikail Cvijic, Chief Admin Officer and GC
25
SEC EDGARLawrence Friedhoff Md. Phd., Chief Development Officer
26
SEC EDGARMarianne L. Romeo, Head,Global Trans & Risk Mgmt
27
SEC EDGARMark Altmeyer, Pres&Chief Commercial Officer
28
SEC EDGARVivek Ramaswamy, Principal Executive Officer
29
SEC EDGARGregory M. Weinhoff, Principal Financial Officer
30
SEC EDGARMichael Adasczik, Principal Accounting Officer
31
SEC EDGAREric Venker, Board member
32
SEC EDGARKristiina Vuori Md., Board member
33
SEC EDGARPavan Cheruvu, Board member
34
SEC EDGARSenthil Vel Sundaram, Board member
35
SEC EDGARGeorge Bickerstaff, Board member
36
SEC EDGARRoger Jeffs, Board member
37
SEC EDGARFrank Torti, Board member
38
SEC EDGARKathryn E. Falberg, Board member
39
SEC EDGARW. Anthony Vernon, Board member
40
SEC EDGARClarence Patrick Machado, Board member
41
SEC EDGARGary P. Pisano, Board member
42
SEC EDGARAtul Pande, Board member
43
SEC EDGARBerndt Modig, Board member
44
SEC EDGARIlan Oren, Board member
45
SEC EDGARLawrence S. Olanoff, Board member
46
SEC EDGARMathew C. Bazley, General counsel
47
SEC EDGARStephen Frederick Mohr, General counsel